Medically Reviewed By: Dr. Imran Khan, MD, IFMCP

Published: October 10, 2026

Finding the Right Path Through Cancer Testing

Possible cancer signs are not always clear, which can make the next testing step difficult to understand. Screening tests look for possible cancer in people without symptoms, while diagnostic tests investigate suspicious signs or results. Other tests may help characterize or monitor cancer after diagnosis.

Research Genetic Cancer Centre (RGCC) testing may provide supplemental laboratory information in selected clinical situations. At Internal Healing & Wellness MD, results are reviewed alongside medical history, pathology, imaging, and oncology recommendations.

Physician discussing PMOS, hormonal health, fertility, and long-term health considerations with a female patient.

Disclaimer: This information is for educational purposes only and is not intended as medical advice. It does not replace, delay, or substitute for standard oncology care, screening, diagnosis, or treatment recommended by your oncology team.

Understanding How RGCC Panels Work

The RGCC test refers to panels that examine circulating tumor cells, molecular markers, or laboratory response patterns. The findings depend on the selected panel and clinical question.

Many RGCC blood tests use a liquid biopsy approach to detect or analyze circulating tumor cells, or CTCs. These are cancer cells shed from a tumor into the bloodstream.

Blood-based RGCC panels do not remove tissue directly from a tumor, although selected tests may also accept tissue samples. For patients already diagnosed or treated for cancer, the findings may provide supplemental biological information during treatment or cancer recurrence monitoring, but they cannot independently confirm recurrence, capture all tumor features, or replace established diagnostic procedures and oncology surveillance.

RGCC’s laboratory holds a CLIA certificate of accreditation. This laboratory certification is separate from FDA approval or clearance of individual tests.

For tumor chemosensitivity/chemoresistance assays, ASCO guidance advises against their use for chemotherapy selection outside clinical trials. Medicare local coverage policy L34554 classifies these assays as investigational and noncovered within its contractor jurisdiction. It does not establish coverage for every RGCC panel or insurer; confirm coverage for the specific test and plan before ordering.

Types of RGCC Tests and What They Examine

RGCC testing includes several panels that assess various laboratory features associated with cancer:

CTC Tests

RGCC Oncocount, Oncotrace, and Oncotrail are designed to detect or analyze CTCs in a blood sample. Depending on the panel, results may include estimated CTC concentration, phenotype and stemness markers, or markers associated with specified cancer types.

Functional Response Tests

RGCC Onconomics evaluates isolated cancer cells against selected chemotherapy agents and targeted therapies under laboratory conditions. Onconomics Plus and Extracts panels may also assess selected natural substances or plant extracts, but these findings do not establish how a patient will respond inside the body.

Molecular and Pharmacogenomic Tests

ArrayCGH examines chromosomal alterations, while ChemoSNiP evaluates genetic variants related to drug metabolism. CAMBISeq analyzes more than 500 cancer-related genes and selected biomarkers. The findings may inform discussions about immunotherapy or targeted therapy but do not guarantee treatment effectiveness.

Immune and Metastatic Profiles

Immune-Frame examines selected immune-cell populations, cell markers, and cytokine activity. Metastat evaluates genes and proteins associated with metastatic potential, but its findings cannot independently confirm cancer spread or progression.

Inside the RGCC Testing Process

How RGCC testing works depends on the panel ordered, but the process begins with a clinical question and ends with a review of the findings. The main steps include:

  • Clinical Review: A healthcare provider considers the diagnosis, medical history, treatment plan, and reason for testing.
  • Panel Selection: The practitioner selects an RGCC test suited to the clinical question.
  • Blood Collection: A trained professional collects and prepares the required blood sample in accordance with laboratory instructions.
  • Laboratory Analysis: The laboratory analyzes the cells, markers, or response patterns included in the selected RGCC panel.
  • Report Preparation: The laboratory summarizes the findings in the RGCC test results.
  • Clinical Discussion: The practitioner reviews the report with pathology, imaging, standard cancer testing, and oncology guidance.

Turnaround varies by panel, shipping, and sample processing. Some circulating tumor cell panels list results within 7 to 10 business days after sample delivery, while certain molecular or sequencing panels may take approximately two to four weeks.

How RGCC Differs From Other Cancer Testing

Cancer tests answer different questions. Some support early cancer detection, while others help confirm a cancer diagnosis, assess inherited risk, or provide information during active cancer treatment. Here are the differences:

Test Sample What It Examines Main Purpose
RGCC Testing Blood or selected tissue CTCs, molecular markers, or response patterns Adds context to personalized cancer care
Tissue Biopsy Tumor tissue Cancer cells and tumor features Helps confirm and classify cancer
Germline Genetic Testing Blood or saliva Inherited genetic variants Assesses hereditary cancer risk
Other Liquid Biopsies Blood Tumor DNA or related material May support certain profiling or monitoring uses
Galleri Test Blood Cancer-associated methylation patterns in cell-free DNA Looks for multiple cancer signals in adults at elevated risk

Two distinctions help explain how the blood-based tests differ.

CTCs and Tumor DNA

Some RGCC panels examine intact circulating tumor cells, while other liquid biopsies analyze circulating tumor DNA released into the blood. The National Cancer Institute describes different liquid biopsy approaches and clinical applications, while emphasizing the need to establish that a test's findings are clinically meaningful (NCI, 2017).

The Galleri Test and Early Cancer Detection

The Galleri test looks for cancer signals in certain adults at elevated risk and is not recommended during active cancer treatment. A Cancer Signal Detected result requires confirmatory diagnostic evaluation, while a No Cancer Signal Detected result does not rule out cancer.

Reading Your RGCC Test Results

An RGCC report organizes the laboratory findings from the selected panel. The results may help patients and practitioners identify questions for further testing or cancer treatment discussions, including:

  • CTC Measurements: Estimates the concentration of circulating tumor cells in the blood sample. Repeat measurements may be compared over time, but cannot independently establish cancer progression or treatment response.
  • Cellular and Molecular Markers: Reports selected features associated with tumor origin, cancer stem cells, gene activity, immune response, or metastatic potential. These findings cannot determine cancer stage or progression on their own.
  • Laboratory Sensitivity Patterns: Describes how sampled cancer cells responded to selected agents outside the body. The report may inform treatment discussions, but cannot predict clinical response with certainty.

RGCC Testing in Integrative Oncology

RGCC testing in integrative oncology allows practitioners to review laboratory findings alongside symptoms, nutrition, supplement use, immune considerations, and quality-of-life goals. The results may also help focus questions about further testing or supportive planning. These cancer-cell panels do not establish dietary or nutrient requirements.

A cancer blood test used in personalized treatment discussions is only one part of the clinical picture. Evidence and clinical use vary by panel, so findings should be interpreted with pathology, imaging, validated molecular profiling, and guidance from the oncology team.

Bring RGCC Results Into the Full Cancer Plan

An RGCC panel should address a defined clinical question, and its report should be reviewed with the records that already guide cancer care. Patients should discuss why a panel is being ordered, what its findings can and cannot show, and whether the result is likely to change supportive planning.

At Internal Healing & Wellness MD, RGCC testing is evaluated as part of a physician-led integrative oncology plan tailored to the patient’s diagnosis, active cancer treatment, symptoms, and goals.

Frequently Asked Questions

Certain RGCC panels are offered to examine potential early cancer signals in a blood sample. However, RGCC testing is not an established replacement for recommended screening tests, diagnostic imaging, or a biopsy when clinically indicated.

A practitioner may consider repeat RGCC testing when there is a specific reason to examine changes over time. There is no universal testing schedule, and the results should not be used to independently determine cancer progression or treatment response.

No. Standard tumor marker tests generally measure specific substances associated with certain cancers, while RGCC panels may examine circulating tumor cells, molecular markers, or laboratory response patterns. Their purpose and clinical evidence vary by test.

RGCC testing is coordinated through a qualified healthcare provider who selects the panel, arranges the blood draw, and reviews the results. Findings should be interpreted in the context of the patient’s diagnosis, medical records, and oncology treatment plan.

No. A negative result means the selected test did not detect its intended target in that sample. It cannot rule out cancer or remove the need for further testing and oncology follow-up.

Schedule a consultation with Internal Healing & Wellness MD today.

Relevant Studies and References